7.37
+0.13(+1.80%)
Currency In USD
| Previous Close | 7.24 |
| Open | 6.97 |
| Day High | 7.37 |
| Day Low | 6.97 |
| 52-Week High | 22.9 |
| 52-Week Low | 6.75 |
| Volume | 17,572 |
| Average Volume | 42,177 |
| Market Cap | 15.3M |
| PE | -0.85 |
| EPS | -8.72 |
| Moving Average 50 Days | 11.26 |
| Moving Average 200 Days | 13.41 |
| Change | 0.13 |
If you invested $1000 in Cadrenal Therapeutics, Inc. Common Stock (CVKD) since IPO date, it would be worth $119.26 as of December 25, 2025 at a share price of $7.37. Whereas If you bought $1000 worth of Cadrenal Therapeutics, Inc. Common Stock (CVKD) shares 1 year ago, it would be worth $448.02 as of December 25, 2025 at a share price of $7.37.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
GlobeNewswire Inc.
Dec 17, 2025 2:00 PM GMT
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced that
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
GlobeNewswire Inc.
Dec 11, 2025 1:05 PM GMT
Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
GlobeNewswire Inc.
Dec 01, 2025 2:00 PM GMT
PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment